Pelvic Inflammatory Disease

Educational clinical summary of Pelvic Inflammatory Disease for doctors and students: definition, workup, management, and key caveats. Not a substitute for guidelines.

Maintained by Dr. Vivek Karn Review process: editorial policy

Disclaimer: This information is intended for educational purposes only and does not constitute medical advice. It is not a substitute for professional medical judgment, diagnosis, or treatment. Clinicians must always use their independent medical judgment, taking into account the individual patient's clinical circumstances, available resources, and the most current evidence-based guidelines. Dosages, indications, and contraindications may change; always consult official prescribing information.

Pelvic Inflammatory Disease

Overview

Definition: Pelvic inflammatory disease (PID) is an acute clinical syndrome resulting from ascending infection of the upper genital tract in women, including the uterus (endometritis), fallopian tubes (salpingitis), ovaries (oophoritis), and surrounding pelvic structures (parametritis, peritonitis). It is a polymicrobial infection, most commonly initiated by sexually transmitted organisms.
Epidemiology:
- PID is a common and serious complication of sexually transmitted infections (STIs), primarily affecting young, sexually active women.
- Estimated incidence in the United States is around 1 in 100 women per year, with a significant proportion of cases being subclinical.
- Highest rates are observed in women aged 15-25 years.
- Disproportionately affects Black and Hispanic women.
- Globally, PID is a major cause of preventable infertility and ectopic pregnancy.
Classification: PID can be classified based on its anatomical extent and severity:
- Endometritis: Inflammation of the uterine lining.
- Salpingitis: Inflammation of the fallopian tubes, the most common and clinically significant component of PID.
- Oophoritis: Inflammation of the ovaries.
- Tubo-Ovarian Abscess (TOA): A collection of pus involving the fallopian tube and ovary, often adherent to other pelvic structures.
- Pelvic Peritonitis: Involvement of the pelvic peritoneum.
- Fitz-Hugh-Curtis Syndrome (Perihepatitis): Inflammation of the liver capsule and adjacent peritoneal surfaces, typically a complication of gonococcal or chlamydial PID, presenting as right upper quadrant pain.

Pathophysiology

Mechanism: PID typically results from an ascending infection. Microorganisms from the vagina and cervix ascend through the cervical canal into the endometrial cavity, fallopian tubes, and sometimes to adjacent peritoneal surfaces.
- Cervical Barrier Compromise: The cervical mucus typically acts as a barrier. Factors that compromise this barrier (e.g., cervicitis, menstruation, instrumentation) increase risk.
- Infectious Agents: The primary pathogens are Neisseria gonorrhoeae and Chlamydia trachomatis. However, PID is often polymicrobial, involving endogenous vaginal flora such as anaerobes (Bacteroides, Peptostreptococcus), Gardnerella vaginalis, Mycoplasma hominis, Ureaplasma urealyticum, and enteric gram-negative rods.
- Inflammatory Response: Infection leads to inflammation, edema, and tissue damage, particularly within the fallopian tubes. This can result in luminal obstruction, ciliary dysfunction, scarring, and adhesions, predisposing to infertility and ectopic pregnancy.
- Tubo-Ovarian Abscess Formation: In severe cases, inflammation can lead to the formation of a tubo-ovarian abscess (TOA), a walled-off collection of pus that can rupture and cause life-threatening peritonitis.
Risk Factors:
- Sexual Activity: Multiple sexual partners, new sexual partner, unprotected sexual intercourse.
- Prior History: Previous episodes of PID (increases risk 2-3 fold).
- STIs: History of N. gonorrhoeae or C. trachomatis infection.
- Age: Young age at first intercourse, and generally women under 25 years old.
- Contraception: Non-barrier methods of contraception (e.g., oral contraceptive pills) are associated with higher risk compared to barrier methods, as they do not protect against STIs. IUD insertion is associated with a small, transient increased risk in the first 3 weeks, especially in women with untreated STIs.
- Vaginal Douching: May alter vaginal flora and push bacteria into the upper genital tract.
- Genital Tract Procedures: Endometrial biopsy, hysteroscopy, D&C, abortion (especially if pre-existing cervicitis).
- Bacterial Vaginosis: May increase susceptibility.
Protective Factors:
- Barrier Contraception: Consistent and correct use of condoms.
- Monogamous Relationships: Reduced exposure to STIs.
- STI Screening and Treatment: Regular screening and prompt treatment of STIs in both partners.
- Avoidance of Vaginal Douching: Maintains normal vaginal flora.

Clinical Presentation

Signs and Symptoms

PID presents with a spectrum of symptoms, from mild/subclinical to severe. - Cardinal Features: * Lower Abdominal Pain: Usually bilateral, dull, aching, constant, non-radiating. Often worsens with ambulation or sexual intercourse. * Abnormal Vaginal Discharge: May be purulent, malodorous, or increased in volume. * Abnormal Uterine Bleeding: Intermenstrual bleeding, post-coital bleeding, or menorrhagia. * Dyspareunia: Deep dyspareunia. * Fever: Temperature ≥38°C (100.4°F). * Chills, Nausea, Vomiting (more common in severe cases). - Early Signs: * Mild, often vague lower abdominal discomfort. * Subtle changes in vaginal discharge. * Irregular bleeding. * Fatigue. - Advanced Signs: * Severe, diffuse lower abdominal pain with guarding and rebound tenderness, indicating peritonitis. * High fever (>39°C). * Signs of systemic toxicity (tachycardia, hypotension in severe cases). * Right upper quadrant pain (Fitz-Hugh-Curtis syndrome). * Palpable tender adnexal mass (Tubo-Ovarian Abscess). - Atypical Presentations: * "Silent PID": Asymptomatic or minimally symptomatic infection that can still lead to tubal damage and infertility. * Right Upper Quadrant Pain: Due to perihepatitis (Fitz-Hugh-Curtis syndrome), often without significant lower abdominal pain. * Gastrointestinal Symptoms: Nausea, vomiting, diarrhea, mimicking gastroenteritis or appendicitis. * Urinary Symptoms: Dysuria, frequency, mimicking urinary tract infection.

Physical Examination

Inspection:
- Assess for general distress, fever, and abdominal distention.
- Speculum exam: Evaluate for purulent or mucopurulent cervical discharge, cervical erythema, or friability. Assess vaginal discharge characteristics.
Palpation:
- Abdominal Palpation: Lower abdominal tenderness (often bilateral), guarding, rebound tenderness.
- Bimanual Pelvic Examination:
  - Cervical Motion Tenderness (CMT): Pain elicited upon movement of the cervix (the "chandelier sign" - patient jumps or reaches for the ceiling due to exquisite pain). This is a cardinal sign.
  - Uterine Tenderness: Pain on palpation of the uterus.
  - Adnexal Tenderness: Tenderness, often bilateral, on palpation of the adnexa (ovaries and fallopian tubes). Unilateral tenderness may suggest other diagnoses (e.g., ectopic pregnancy, appendicitis) or a unilateral TOA.
  - Adnexal Mass: A palpable, often tender, ill-defined mass may indicate a tubo-ovarian abscess (TOA).

Diagnostic Approach

PID is primarily a clinical diagnosis based on symptoms and physical exam findings, as definitive diagnosis by laparoscopy is invasive and not routinely performed. A high index of suspicion is crucial to initiate timely treatment and prevent long-term sequelae.

History Taking

Key Questions:
- Chief Complaint: Detailed history of pelvic/abdominal pain (onset, character, location, radiation, duration, aggravating/alleviating factors).
- Associated Symptoms: Vaginal discharge, abnormal bleeding, dyspareunia, fever, chills, nausea, vomiting, urinary/GI symptoms.
- Sexual History: Number of partners, new partners, condom use, history of STIs, partner's STI status, partner treatment.
- Contraceptive Use: Especially IUD use (recent insertion within 3 weeks).
- Gynecological History: Last menstrual period, history of PID, ectopic pregnancy, infertility, gynecological procedures, douching practices.
- Medical History: Any immunocompromise (e.g., HIV).
- Pregnancy Status: Always rule out pregnancy in women of reproductive age with abdominal pain.
Red Flags:
- Signs of peritonitis (rebound, guarding).
- Hemodynamic instability (hypotension, tachycardia).
- High fever (>39°C) with chills.
- Evidence of a ruptured TOA or suspected intra-abdominal hemorrhage.
- Inability to tolerate oral antibiotics.
- Pregnancy (requires inpatient management).
- Immunocompromised status.
- Lack of clinical response to oral antibiotics within 48-72 hours.
- Suspicion of other surgical emergencies (e.g., appendicitis, ectopic pregnancy).

Laboratory Tests

First-Line:
- Pregnancy Test: Urine or serum β-hCG to rule out ectopic pregnancy (critical).
- STI Testing:
  - Nucleic Acid Amplification Tests (NAATs) for N. gonorrhoeae and C. trachomatis from endocervical or vaginal swabs. This is essential, even though negative tests do not rule out PID (due to polymicrobial nature).
- Complete Blood Count (CBC): May show leukocytosis with left shift, but a normal WBC count does not exclude PID.
- Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein (CRP): Often elevated in PID, indicating inflammation, but are non-specific.
Confirmatory (Supportive, not diagnostic in isolation):
- Vaginal Microscopy (Wet Mount): Saline wet mount may show clue cells (if bacterial vaginosis is co-present), trichomonads, or increased number of polymorphonuclear leukocytes (PMNs) (>1 WBC per epithelial cell is suggestive of cervicitis/endometritis). A positive whiff test may also be present.
- Endocervical Gram Stain: If available, gram-negative intracellular diplococci suggest N. gonorrhoeae.
- HIV and Syphilis Serology: Recommended for all patients diagnosed with an STI or PID, given common co-occurrence.
Monitoring:
- STI Test of Cure: For N. gonorrhoeae, a test of cure (TOC) using NAAT is recommended 7-14 days after treatment, especially if using alternative regimens.
- Rescreening: All women treated for C. trachomatis or N. gonorrhoeae (including those with PID) should be rescreened approximately 3 months after treatment, as reinfection rates are high.

Imaging

Recommended:
- Transvaginal Ultrasonography (TVS):
  - Purpose: To support the diagnosis, evaluate for complications (e.g., tubo-ovarian abscess), and rule out other causes of pelvic pain (e.g., ectopic pregnancy, ovarian torsion, appendicitis, endometrioma).
  - Findings: May show thickened, fluid-filled fallopian tubes (salpingitis), cogwheel sign (transverse septations within the tube), hydrosalpinx, free pelvic fluid, or a tubo-ovarian abscess (TOA) appearing as a complex, multiloculated adnexal mass. Doppler may show increased vascularity.
- Indications: If the diagnosis is uncertain, if an adnexal mass is suspected, or if the patient does not respond to antibiotic therapy within 48-72 hours.
Advanced:
- Computed Tomography (CT) Scan:
  - Purpose: Useful for distinguishing PID from other causes of acute abdominal pain (e.g., appendicitis, diverticulitis, urolithiasis), particularly in cases where ultrasound is inconclusive or to better delineate a large or complex TOA. Less sensitive than MRI for pure salpingitis.
- Magnetic Resonance Imaging (MRI):
  - Purpose: Highly sensitive and specific for detecting PID and its complications (e.g., TOA, hydrosalpinx). Can provide excellent soft tissue detail.
  - Indications: Reserved for complex or atypical cases where ultrasound and CT are inconclusive, or when radiation exposure is a concern (e.g., younger patients). Not typically a first-line diagnostic tool due to cost and availability.
- Laparoscopy:
  - Purpose: Historically considered the gold standard for diagnosing PID, allowing direct visualization of inflamed fallopian tubes, adhesions, and purulent exudate. Biopsies can be taken.
  - Indications: Rarely used for routine diagnosis due to invasiveness. May be considered if diagnosis remains uncertain after non-invasive tests, if other surgical emergencies cannot be excluded (e.g., appendicitis), or for surgical management of complicated PID (e.g., drainage of TOA unresponsive to medical therapy).

Management

Timely and appropriate treatment of PID is critical to prevent severe acute complications and long-term sequelae such as chronic pelvic pain, infertility, and ectopic pregnancy. Treatment is primarily antibiotic-based and should be initiated empirically due to the polymicrobial nature of the infection and the potential for severe consequences if treatment is delayed.

Acute Management

Immediate (Initial 24 hours):
- Empiric Antibiotics: Administer broad-spectrum antibiotics promptly based on clinical suspicion, before definitive test results are available. Coverage must include N. gonorrhoeae, C. trachomatis, and anaerobic/facultative bacteria.
- Pain Management: Provide adequate analgesia (e.g., NSAIDs, opioids if severe).
- Antiemetics: If nausea and vomiting are present.
- Hydration: IV fluids if patient is dehydrated or unable to tolerate oral intake.
Stabilization:
- Assess Severity: Determine if inpatient or outpatient management is appropriate (see inpatient criteria below).
- Monitor Vitals: Closely monitor vital signs for signs of worsening infection or sepsis.
- Patient Education: Counsel on the importance of completing the full course of antibiotics and partner treatment.
Emergency:
- Hospitalization: Indicated for:
  - Surgical emergencies cannot be excluded (e.g., appendicitis, ectopic pregnancy, ovarian torsion).
  - Tubo-ovarian abscess (TOA) suspected.
  - Pregnancy.
  - Severe illness (high fever, nausea/vomiting, severe abdominal pain).
  - Immunocompromised status (e.g., HIV infection with low CD4 count, immunosuppressive therapy).
  - Failure of outpatient oral antibiotic therapy within 48-72 hours.
  - Inability to tolerate oral antibiotics.
- Surgical Consultation: For suspected ruptured TOA, peritonitis, or TOA that does not respond to medical management.

Chronic Management

Pharmacological: While acute PID requires antibiotics, there is no "chronic pharmacological management" in terms of continuous antibiotics. The focus is on preventing recurrence and managing long-term sequelae.
Non-pharmacological:
- Partner Treatment: Crucial to prevent reinfection. All sexual partners from the preceding 60 days should be evaluated and treated empirically for N. gonorrhoeae and C. trachomatis, regardless of their symptoms or test results.
- Sexual Abstinence: Advise abstinence from sexual intercourse until the patient and all partners have completed treatment and symptoms have resolved.
- Safe Sexual Practices: Counseling on consistent condom use, limiting partners, and regular STI screening.
- Follow-up: Re-evaluation by a clinician within 2-3 days of initiating treatment is recommended to ensure clinical improvement, especially for outpatient regimens.
Monitoring:
- Symptom Resolution: Confirm resolution of pain, fever, and discharge.
- Repeat STI Testing: Rescreen for C. trachomatis and N. gonorrhoeae 3 months after treatment, particularly for women under 25, due to high rates of reinfection. Test of cure for N. gonorrhoeae is recommended 7-14 days after treatment.
- Screening for Long-term Complications: Discuss risk of chronic pelvic pain, infertility, and ectopic pregnancy, and provide appropriate referral if these complications arise.

Treatment Algorithms (Based on CDC 2021 STI Treatment Guidelines)

Key Principle: All regimens must provide coverage against N. gonorrhoeae, C. trachomatis, and anaerobes.

Outpatient Management (Mild to Moderate PID)

Criteria: Patient meets diagnostic criteria for PID, does not meet inpatient criteria, is reliable for follow-up, and can tolerate oral medications.
First-Line Regimen (Preferred):
- Ceftriaxone 500 mg IM in a single dose (for patients weighing <150 kg; for patients ≥150 kg, 1 g IM is recommended)
- PLUS Doxycycline 100 mg orally twice a day for 14 days
- PLUS Metronidazole 500 mg orally twice a day for 14 days
  - Rationale: Ceftriaxone provides excellent gonococcal coverage. Doxycycline covers chlamydia and a broad spectrum of other atypical and facultative organisms. Metronidazole covers anaerobes and is particularly important if bacterial vaginosis is co-present or if a tubo-ovarian abscess is suspected.
Follow-up: Re-evaluate within 48-72 hours. If no clinical improvement, hospitalization and parenteral therapy should be considered, along with re-evaluation of diagnosis.

Inpatient Management (Severe PID, TOA, or other indications for hospitalization)

Criteria: Patient meets any of the inpatient criteria listed above.
First-Line Regimens (Parenteral):
- Regimen A (Preferred):
  - Cefotetan 2 g IV every 12 hours
  - OR Cefoxitin 2 g IV every 6 hours
  - PLUS Doxycycline 100 mg orally or IV every 12 hours.
  - Rationale: Cefotetan/Cefoxitin are second-generation cephalosporins with excellent coverage against anaerobes and N. gonorrhoeae. Doxycycline provides chlamydial and broad atypical coverage.
- Regimen B (Alternative for penicillin-allergic patients or if concerns for resistant organisms):
  - Clindamycin 900 mg IV every 8 hours
  - PLUS Gentamicin loading dose 2 mg/kg IV, followed by a maintenance dose of 1.5 mg/kg IV every 8 hours OR a single daily dose of 3-5 mg/kg IV.
  - Rationale: Clindamycin provides excellent anaerobic coverage. Gentamicin provides broad-spectrum gram-negative coverage. This regimen lacks strong N. gonorrhoeae coverage if used alone.
Duration: Continue parenteral therapy for at least 24-48 hours after clinical improvement (afebrile, decreasing abdominal tenderness, decreasing WBC count).
Transition to Oral Therapy: After clinical improvement, transition to oral antibiotics to complete a full 14-day course.
- Follow-up Oral Regimen: Doxycycline 100 mg orally twice a day PLUS Metronidazole 500 mg orally twice a day.
  - Rationale: This regimen maintains broad coverage for chlamydia, anaerobes, and other aerobes.

Management of Tubo-Ovarian Abscess (TOA)

Initial Management: All TOAs require inpatient management with intravenous broad-spectrum antibiotics. Regimens for inpatient PID are appropriate.
Monitoring: Closely monitor clinical response. Most TOAs (up to 70-80%) resolve with antibiotic therapy alone.
Surgical/Radiological Intervention:
- Indications: Ruptured TOA (surgical emergency), unruptured TOA that does not respond to 48-72 hours of IV antibiotics, or a large (typically >7-10 cm) or increasing size TOA.
- Options: Percutaneous drainage (CT or ultrasound guided) or surgical drainage (laparoscopy or laparotomy). Hysterectomy with bilateral salpingo-oophorectomy may be necessary in severe, recurrent, or refractory cases, particularly if fertility is not desired or the TOA is very large and destructive.
- IUD Removal: If a patient with an IUD develops PID, the IUD does not need to be removed immediately if the patient is responding to antibiotics and does not have a TOA. If there is no clinical improvement within 48-72 hours, or if a TOA is present, IUD removal should be considered after initiating antibiotic therapy.

Refractory Cases

Re-evaluation: If a patient does not respond to initial treatment, re-evaluate the diagnosis (e.g., consider appendicitis, ovarian torsion, diverticulitis, urinary tract infection, endometriosis, adnexal mass).
Compliance: Assess medication adherence and partner treatment.
Antibiotic Resistance: Consider potential for antibiotic resistance (e.g., fluoroquinolone-resistant N. gonorrhoeae).
Surgical Consultation: For ongoing concerns, especially if a TOA is present or other surgical pathology is suspected.

Complications

Common:
- Chronic Pelvic Pain (CPP): Occurs in up to 30% of women following PID, due to adhesions, inflammation, and nerve damage.
- Infertility (Tubal Factor): PID is a leading cause of tubal factor infertility, with risk increasing with the number and severity of PID episodes. One episode: 8-10% risk; two episodes: 20-25% risk; three or more episodes: 50% risk.
- Ectopic Pregnancy: Damage to fallopian tubes increases the risk of subsequent ectopic pregnancy by 6-10 times.
- Dyspareunia: Painful intercourse due to scarring and adhesions.
- Recurrent PID: Increased risk of future PID episodes.
Serious:
- Tubo-Ovarian Abscess (TOA): Can be life-threatening if ruptured.
- Ruptured TOA: Leads to diffuse peritonitis, septic shock, and can be fatal if not promptly managed surgically.
- Sepsis: Systemic inflammatory response to severe infection.
- Fitz-Hugh-Curtis Syndrome (Perihepatitis): Inflammation of the liver capsule causing right upper quadrant pain, often referred to the right shoulder. Can lead to "violin string" adhesions between the liver and abdominal wall.
Long-term:
- Psychological impact from chronic pain, infertility, and recurrent infections.
- Increased risk of adverse pregnancy outcomes (e.g., preterm birth, miscarriage) in future pregnancies.

Prognosis

Factors Affecting Outcome:
- Severity of Initial Infection: More severe PID, especially with TOA, correlates with worse outcomes.
- Number of PID Episodes: Recurrent PID significantly increases the risk of infertility and chronic pain.
- Promptness and Adequacy of Treatment: Early and effective antibiotic treatment improves outcomes.
- Microorganisms Involved: N. gonorrhoeae and C. trachomatis are particularly damaging to fallopian tubes.
- Age: Younger women may be at higher risk for severe sequelae if infection is not treated promptly.
Survival: PID itself is rarely fatal. However, complications like ruptured TOA with resulting sepsis carry a significant mortality risk if not treated immediately.
Quality of Life: Chronic pelvic pain, infertility, and psychological distress associated with these conditions can significantly impair a woman's quality of life. Counseling and support are essential.

Prevention

Primary Prevention: Aimed at preventing the initial occurrence of STIs and PID.
- Sexual Education: Promoting safe sexual practices (e.g., consistent and correct condom use, limiting number of sexual partners).
- STI Screening: Regular screening for N. gonorrhoeae and C. trachomatis in sexually active women, particularly those under 25 years and those with risk factors.
- Abstinence from Douching: Counsel women against douching.
- Partner Notification and Treatment: Essential for preventing reinfection.
Secondary Prevention: Early detection and intervention to prevent progression or complications.
- Prompt Diagnosis and Treatment: Rapid diagnosis and adequate treatment of cervicitis and acute PID to prevent progression to chronic damage.
- Rescreening: Rescreening for STIs 3 months after treatment to detect and treat reinfection early.
Tertiary Prevention: Preventing or minimizing the long-term sequelae of PID.
- Adherence to Treatment: Emphasize the importance of completing the full antibiotic course.
- Follow-up: Regular follow-up to assess for symptom resolution and identify complications.
- Management of Complications: Timely management of chronic pelvic pain, referral for fertility services, and management of ectopic pregnancy.

Special Populations

Pediatric/Adolescent:
- PID in sexually active adolescents is common and should be suspected in sexually active girls presenting with lower abdominal pain.
- Management is similar to adults. Ensure privacy and confidentiality for sexual history taking.
- High risk for reinfection; emphasize STI prevention and partner treatment.
Geriatric:
- PID is rare in postmenopausal women unless associated with procedures (e.g., endometrial biopsy), gynecologic malignancy, or other predisposing factors that breach natural barriers.
- Diagnosis can be challenging due to atypical presentation and comorbidities.
- Management involves broad-spectrum antibiotics, often requiring inpatient care due to potential for more severe infection and comorbidities.
Pregnancy:
- PID in pregnancy is rare (estimated 1 in 1,000 to 1 in 10,000 pregnancies), primarily occurring in the first trimester.
- Risk: Associated with an increased risk of septic abortion, preterm labor, premature rupture of membranes, and maternal sepsis.
- Management: Requires hospitalization and prompt intravenous broad-spectrum antibiotics. Regimens must be safe in pregnancy (e.g., avoid tetracyclines, quinolones).
  - Example: Clindamycin + Gentamicin (as per inpatient Regimen B) OR Cefoxitin/Cefotetan + Azithromycin (instead of doxycycline).
- Tubo-Ovarian Abscess in Pregnancy: Extremely serious, often requires prompt surgical or percutaneous drainage if present.
Comorbidities (e.g., HIV Infection):
- Women with HIV infection and PID may experience more severe disease and a higher rate of TOA formation.
- Treatment regimens for PID are generally the same, but hospitalization and parenteral antibiotics should be considered more readily, and a longer duration of therapy may be warranted.
- Response to therapy should be closely monitored.
- Antiretroviral therapy should be continued.

Clinical Pearls

Diagnostic:
- High Index of Suspicion: PID is a clinical diagnosis; don't wait for definitive lab results. Err on the side of treatment to prevent complications.
- "Chandelier Sign": Exquisite cervical motion tenderness is a classic, though non-specific, finding.
- Rule Out Pregnancy: Always perform a pregnancy test to exclude ectopic pregnancy, which can mimic PID and is a surgical emergency.
- Minimal Criteria: Diagnosis can be made with minimal criteria (lower abdominal pain + CMT, uterine tenderness, or adnexal tenderness).
- Polymicrobial Nature: Remember PID is polymicrobial, often involving both STIs and endogenous flora.
Treatment:
- Empiric and Prompt: Initiate broad-spectrum antibiotics as soon as PID is suspected.
- Partner Treatment is Crucial: Essential to prevent reinfection.
- Complete the Full Course: Emphasize adherence to the entire 14-day antibiotic course, even if symptoms improve quickly.
- IUD and PID: IUD removal is generally not necessary unless there is no improvement with antibiotics within 48-72 hours or if a TOA is present.
- Consider Metronidazole: Always include metronidazole in outpatient regimens, especially with suspected anaerobes or TOA.
Pitfalls:
- Misdiagnosis: Confusing PID with other conditions like appendicitis, ectopic pregnancy, ovarian torsion, UTI, or endometriosis.
- Under-treatment: Inadequate duration or spectrum of antibiotics.
- Failure to Treat Partners: Leading to reinfection.
- Missing TOA: Not performing imaging when clinically indicated.
- Delay in Surgical Consultation: For ruptured TOA or cases unresponsive to medical management.

Recent Updates

Guidelines: The most recent comprehensive guidelines are the CDC 2021 STI Treatment Guidelines, which provide updated recommendations for diagnosis and management of PID, including specific antibiotic regimens and criteria for hospitalization.
Evidence: Ongoing research continues to refine optimal antibiotic regimens, duration of treatment, and the role of anti-inflammatory agents. Increased focus on early detection of asymptomatic PID and its impact on long-term sequelae. The understanding of the vaginal microbiome's role in PID susceptibility is evolving.
Controversies:
- Routine Metronidazole: While increasingly recommended, the necessity of metronidazole for all outpatient PID cases (especially in the absence of BV symptoms or TOA) remains a point of discussion. However, current guidelines strongly recommend it.
- Laparoscopy: The role of diagnostic laparoscopy has significantly diminished due to improved imaging and the desire for less invasive diagnosis, but it remains the gold standard in specific, complicated cases.
- IUD Removal: The timing and necessity of IUD removal in PID cases continue to be debated, with current consensus leaning towards not removing it unless there is no response to antibiotics or a TOA is present.

Key References

Guidelines:
- Centers for Disease Control and Prevention (CDC). Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep 2021;70(4):1–187.
- American College of Obstetricians and Gynecologists (ACOG). Practice Bulletin No. 222: Pelvic Inflammatory Disease. Obstet Gynecol. 2020 Jul;136(1):e31-e40.
Studies:
- Svensson L, Weström L, Ripa KT, et al. Differences in some clinical and laboratory parameters in acute salpingitis related to culture and serologic findings. Am J Obstet Gynecol. 1984;149(2):111-118.
- Ross JD, Cronjé HS, Butler LC, et al. A multicenter, open-label, randomized clinical trial to compare the efficacy and safety of oral ciprofloxacin with oral doxycycline in the treatment of uncomplicated acute pelvic inflammatory disease. Sex Transm Dis. 1999;26(1):15-21.
Reviews:
- Workowski KA, Bolan E. Sexually Transmitted Infections Treatment Guidelines, 2015. MMWR Recomm Rep 2015;64(RR-3):1–137. (Predecessor to 2021 guidelines, still provides background)
- Brunham RC, Gottlieb SL, Paavonen J. Pelvic inflammatory disease. N Engl J Med. 2015;372(21):2039-2049.